Profile data is unavailable for this security.
About the company
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-53.93m
- Incorporated2011
- Employees11.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
Mergers & acquisitions
Acquired company | RENB:NAQ since announced | Transaction value |
---|---|---|
Gedi Cube Bv | -52.98% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 216.82m | 49.00 | -- | 4.88 | -- | 2,676.83 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Zura Bio Ltd | 0.00 | -60.18m | 223.53m | 14.00 | -- | 2.51 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Omeros Corp | 0.00 | -179.09m | 224.82m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Mersana Therapeutics Inc | 38.30m | -134.81m | 225.14m | 123.00 | -- | 8.05 | -- | 5.88 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 225.46m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -124.58m | 228.49m | 140.00 | -- | 1.44 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Solid Biosciences Inc | 0.00 | -90.25m | 229.13m | 88.00 | -- | 1.07 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 231.11m | 13.00 | 1.89 | 0.6603 | 7.55 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 233.01m | 135.00 | -- | 8.72 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Renovaro Inc | 0.00 | -53.93m | 233.06m | 11.00 | -- | 1.38 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Sutro Biopharma Inc | 154.07m | -114.96m | 235.57m | 300.00 | -- | 1.84 | -- | 1.53 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 236.66m | 133.00 | -- | 1.28 | -- | 222.43 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Eliem Therapeutics Inc | 0.00 | -14.53m | 237.71m | 9.00 | -- | 1.79 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 247.13m | 168.00 | -- | 0.5387 | -- | 6.09 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Black Diamond Therapeutics Inc | 0.00 | -79.79m | 249.76m | 54.00 | -- | 2.24 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.90m | 2.65% |
Geode Capital Management LLCas of 31 Mar 2024 | 437.97k | 0.30% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 373.60k | 0.25% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 306.14k | 0.21% |
Millennium Management LLCas of 31 Mar 2024 | 293.63k | 0.20% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 257.04k | 0.17% |
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 187.45k | 0.13% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 178.09k | 0.12% |
Jane Street Capital LLCas of 31 Mar 2024 | 133.84k | 0.09% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 120.35k | 0.08% |